We Proudly Offer Free Shipping On All Orders!



New ValidCare Study Reports No Liver Toxicity When Using CBD

Posted by Kerry Hinkle on

New ValidCare Study Shows No Liver Toxicity With CBD

Teachers standing around examining results of scientific study.

In a groundbreaking announcement, ValidCare just submitted their report to the FDA’s Cannabis Product Council regarding their liver toxicity study with people who consume Hemp-Derived CBD.

According to their press release, “preliminary findings show no evidence of liver disease in the 839 participants and no increase in the prevalence of elevated liver function tests”. 

This announcement is HUGE for anyone in the Hemp industry. Dating back to when to the 2018 Farm Bill first passed, the FDA has continually pushed the narrative that they aren’t able to regulate CBD because of the lack of science-based evidence.

In May of 2019 the FDA held a public docket regarding CBD, in July 2020 they collected stakeholder & industry input, and in November of 2020 the FDA held a scientific conference. In all three of these instances, they pushed for the need for more scientific research into Hemp-Derived CBD.

Well, our industry heard their cry for more research and responded in a rather enormous way.

Today we’re going to examine the details behind the new ValidCare liver study, why the results of this study are so important for the Hemp industry, and what these results could mean going forward.

Why The ValidCare Liver Toxicity CBD Study Was Needed

As we just pointed out, the FDA has been stating for years that they aren’t able to regulate CBD because of the lack of scientific evidence.

In fact, on March 5th 2020, the FDA reported to Congress the need for science-based data to determine the appropriate regulatory pathway for Hemp-Derived CBD products. 

With the FDA not regulating CBD, that has allowed for bad actors to flood the Hemp industry damaging the reputation & integrity of companies that are in this industry for the right reasons.

.

These exact concerns led one of the co-founders of the study, Dr. Keith Aqua, to say We are encouraged by these findings and hopeful this study provides FDA with sufficient science-based data to determine and take action on a safe regulatory path forward”

Dr. Aqua’s comment made clear the intent & purpose of this study was to begin the process of regulating Hemp & CBD products on the market.

The leaders of the Hemp industry have been clamoring for more government intervention for years, knowing this type of regulation will only help the good actors in our industry, and provide more consumer confidence in our products. 

That’s why the U.S. Hemp Authority was formed, and that’s why some of our industries biggest companies help fund this ValidCare CBD study. With more scientific research into this product, we’re confident that government agencies will begin to recognize all of the potential with Hemp & CBD.

The results of this study came back overwhelmingly positive for the Hemp industry. Because of this new research showing CBD isn’t harmful to the liver, we can begin to prove to the FDA & other government agencies that access to these products should be made widely available. 

What The ValidCare Liver Toxicity Study Means For The CBD Industry Going Forward

This new evidence shows that CBD can be generally safe on our liver. Out of the 839 participants in this study, only three showed high levels of liver enzymes ALT. All three of these participants were also on prescription medicines that are known to elevate liver enzymes. So, easily explainable there.

Along with the exciting news regarding liver toxicity, there was also a positive development in how we think about CBD interacting with prescription medications.

We want to be clear this was not a definitive result from this study, just simply a positive unintended finding as a result of doing scientific research into CBD.

According to ValidCare, “Almost 70% of the study participants reported having a medical condition and taking medications for those conditions, without an increase in reporting of adverse events”. 

Again, while this isn’t definitive results, it’s positive news in how we think CBD could interact with medications people are currently taking. The fact that the majority of the population in this study was able to take CBD consistently for 60 days with no interruption in their daily medications helps the case that CBD should be made widely available to all who want to use it.

Red sign that reads thank you.

We'd also like to give a special shoutout to the 12 companies that help fund this ValidCare report. Links to their website are attached to each name, with many of them being certified by the U.S. Hemp Authority. We thank each & everyone of these companies for their participation in moving the Hemp & CBD industry forward.

 

 

The content on this site is not intended to be a substitute for professional medical advice, diagnosis or treatment. While research has shown that CBD has the potential to help provide beneficial outcomes for several complaints, it is advisable to seek the advice of a physician or other qualified healthcare provider when you have questions regarding any medical condition and when starting, augmenting or discontinuing any existing health routine. 

FDA Disclaimer: Any statements made within this website have not been evaluated by the Food and Drug Administration. No products produced, manufactured, marketed, or distributed are intended to diagnose, treat, cure or prevent any disease. Consult your physician before beginning any supplements or botanical extracts. If pregnant or breast feeding, consult with your physician before use. For use by adults 18+. Keep out of reach of children.

0 comments

Leave a comment

Please note, comments must be approved before they are published